Pharma and life sciences · Regulatory information and pharmacovigilance software
Miss the milestone and the incumbent stays for years.
You sell RIM, submission, UDI or safety database software to regulatory and drug safety leaders. Buyers switch at a milestone: a Phase 3 start, a filing or an acquisition. By our estimate, buying starts 6–12 months before the milestone, so a vendor who waits for the announcement arrives late.
- Safety database deal, converted from US dollars
- €36–356k a year Illustrative
- Mid-size pharma cycle
- 4–18 months Illustrative
- Buying panel
- 5–12 people Illustrative
Updated 5 October 2026 · Based on Panelhop research, October 2026
At a mid-size pharma company with marketed products5–12 people Illustrative
- Head of pharmacovigilance (safety database deals), can veto
- Head of regulatory affairs (RIM and submission deals), can veto
- Regulatory and PV operations
- IT and computerised system validation, can veto
- Information security and data protection, can veto
- Procurement and finance, can veto
- Regulatory consultant or CRO
The short answer
How do RIM and pharmacovigilance vendors sell to biopharma and medtech companies?
RIM, submission and pharmacovigilance vendors sell to regulatory affairs teams at biopharma and medtech companies and to drug safety teams at biopharma. Buyers change these systems mostly at milestones. By our estimate, mid-size pharma deals take 4–18 months and open on a Phase 3 start, a filing or an acquisition; at device makers, EUDAMED registration opens them too.
Regulatory information and pharmacovigilance software · How a deal really moves
Phase 3 is public. The database is chosen. QA arrives after the shortlist, and the deal misses the budget. The same deal, timed to the milestone. Phase moves flagged weekly, and QA in before the shortlist.
One mid-size pharma company, 5–12 people and an estimated 4–18 months from first signal to signature.
What opens a deal
- Phase 3 start or filing: Milestone
- Acquisition closes: Consolidation
- EUDAMED legacy registration: Deadline · EU
- EU pharma legislation reform: Regulation · EU
- New head of PV or regulatory: Leadership
Signal Desk · weekly: In-market accounts, scored and mapped
Your buyer and who decides
A mid-size pharma company
Also biotechs, medtech and top-tier pharma
671 pharma companies in Germany alone
Panel Check · coverage baselined
- Head of PV or regulatory, can Veto: Lost case history, or a missed submission date.
- IT and validation, can Veto: A vendor release that breaks the validated state.
- Procurement and finance, can Veto: Per-case or per-user fees that rise with each launch.
- Security and privacy, can Veto: Patient case data held where the DPA does not allow it.
- Regulatory and PV ops: Double entry during months of parallel running.
- Consultant or CRO: Losing scope to the vendor’s own services team.
How the deal moves
Targeting Typical time: 2–8 weeks
- Where it stalls
- Phase 3 goes public with the database chosen
- With Panelhop: Signal Desk
- Phase moves, filings and new safety leaders, in your CRM weekly
Business case Typical time: 1–3 months
Requirements Typical time: 3–8 weeks
Evaluation Typical time: 1–3 months
- Where it stalls
- IT says wait for the platform’s own module
- With Panelhop: Leak Fix
- IT, validation, security and data protection mapped on every account
Supplier qualification Typical time: 2–6 months
- Where it stalls
- QA and the DPO meet you after the shortlist
- With Panelhop: Leak Fix
- Supplier qualification opened at discovery, its days in the forecast
Contract Typical time: 1–3 months
- Where it stalls
- No funded line, so the deal waits a year
- With Panelhop: Leak Fix
- Deals without a funded budget line flagged before the forecast call
Migration Typical time: 6–12+ months
Expansion
Panel Ops · monthly: Scores and plays tuned against the baseline
Illustrative Source: Stages, seats, triggers and stalls from Panelhop research, October 2026; BPI (Bundesverband der Pharmazeutischen Industrie), citing Destatis structural statistics; the services as described on the Services page. Note: Durations, panel sizes and cycle lengths are Panelhop estimates from our research, not measurements.
At a glance
| Safety database deal, converted from US dollars | €36–356k a year Illustrative |
|---|---|
| Mid-size pharma cycle | 4–18 months Illustrative |
| Buying panel | 5–12 people Illustrative |
| Implementation | 6–12 months or more for an enterprise safety database Illustrative |
Source: Panelhop research, October 2026. Note: Values marked Illustrative are Panelhop estimates from our research, not measurements.
Regulatory and safety pipelines leak at the milestone.
Why do RIM and safety database deals stall?
RIM and safety database deals stall where milestones are tracked too late and the CRO’s role is unknown. They also stall when one function head sells alone, supplier qualification sits outside the forecast and customer acquisitions go unwatched.
Where the pipeline leaks: 5 points across 8 stages.
The Phase 3 news arrives with the database chosen
- What you see
- A biotech announces Phase 3 or a filing with its safety database already chosen.
- Why it happens
- No field holds each account’s phase, filing date or safety arrangement. In our analysis of life sciences vendors’ websites, none of the 13 vendors segments by clinical phase or regulatory deadline.
Stage Targeting
‘Our CRO handles safety’, and the account goes quiet
- What you see
- A biotech says its CRO handles safety, and the account goes quiet.
- Why it happens
- Nobody records which CRO holds each sponsor’s safety data, or when a phase move makes the sponsor likely to bring safety in-house.
Stage Targeting
The head of PV says yes, then IT objects
- What you see
- The head of PV backs the purchase, then IT raises the integration objection late.
- Why it happens
- The deal runs single-threaded to one function head. In our analysis of life sciences vendors’ websites, single-threaded deals were a likely bottleneck for 10 of the 13 vendors.
Stage Evaluation
Close dates move for months in supplier audit
- What you see
- Close dates move for months while the deal sits in supplier audit and privacy review.
- Why it happens
- Supplier audit, security and data protection review are not stages in the CRM. In our analysis of life sciences vendors’ websites, late supplier qualification was a likely bottleneck for 12 of the 13 vendors.
Stage Supplier qualification
Your customer is acquired, and you hear at renewal
- What you see
- An acquired customer moves to the acquirer’s safety platform at renewal.
- Why it happens
- Customer M&A is not recorded as an account event, so the risk surfaces only on the renewal date.
Stage Expansion
Phase moves and deadlines reopen regulatory and safety systems.
What makes a biopharma or medtech company buy new regulatory or safety software?
Biopharma and medtech companies buy new regulatory or safety software at a phase move, a filing or an acquisition. A regulatory deadline or a new safety or regulatory leader opens windows too. Registries, filings and press releases make most of them public.
The 5 events that open or close the window for a deal.
Budget cycle
Phase 3 start, filing or approval
- What happens
- A Phase 3 start, a BLA or NDA filing or an approval leaves the sponsor needing a validated safety database and submission tools.
- Where to spot it
- CTIS, company press releases, investor decks and PDUFA dates.
- Window
- Opens 6–12 months before the milestone.
Consolidation
Acquisition closes
- What happens
- Integration teams choose which safety and regulatory systems to keep, and safety cases migrate to one database.
- Where to spot it
- M&A trackers and closing notices in company filings.
- Window
- Planning starts at signing; purchases follow 0–12 months after close.
Regulation
EUDAMED legacy registration
- What happens
- The first EUDAMED modules became mandatory on 28 May 2026, and devices already on the EU market that are still being placed on it must be registered in the UDI/device module by 28 November 2026.
- Where to spot it
- The European Commission’s EUDAMED pages, each maker’s registered devices and UDI or regulatory data job postings.
- Window
- Open now to the end of 2026, with device data governance work through 2027.
Regulation
EU pharmaceutical legislation
- What happens
- The European Parliament and Council reached political agreement on the reformed EU pharmaceutical legislation on 11 December 2025, with the new rules applying from 2028.
- Where to spot it
- EMA’s reform page and its implementation guidance.
- Window
- Regulatory teams update registration, submission and shortage-reporting processes as guidance lands, through 2028.
Leadership
New head of safety or regulatory affairs
- What happens
- A new head of pharmacovigilance, QPPV or regulatory affairs reviews the systems and providers behind the function.
- Where to spot it
- Industry appointment roundups and job changes at target accounts.
- Window
- Opens 3–9 months after the start date.
Safety or regulatory heads buy; IT and QA can veto.
Who decides on a safety database or RIM purchase at a pharma company?
The head of pharmacovigilance usually buys the safety database and the head of regulatory affairs buys RIM; both sit on the panel when one platform covers both. Operations teams shape the requirements, and IT, validation, security, data protection and finance can each stop the deal. At a device maker buying UDI or EUDAMED tools, regulatory affairs runs the purchase with QA and IT.
At a mid-size pharma company with marketed products, 5–12 people sit on the panel and 5 seats can stop the deal.
At a mid-size pharma company with marketed products: 5–12 people
Head of pharmacovigilance (safety database deals)
Can Veto
VP Global Patient Safety · Head of Pharmacovigilance · QPPV
- Cares about
- Cases processed on time and signal detection that stands up at inspection.
- Worries about
- Losing case history or audit trail in a migration.
Head of regulatory affairs (RIM and submission deals)
Can Veto
Head of Regulatory Affairs · Chief Regulatory Affairs Officer
- Cares about
- Registrations, submissions and variations tracked in one place.
- Worries about
- A missed submission date or a registration out of step with the dossier.
Regulatory and PV operations
Regulatory Operations Manager · PV Operations Lead
- Cares about
- Fewer manual steps and clean data across products and countries.
- Worries about
- Double entry during months of parallel running.
IT and computerised system validation
Can Veto
IT Business Partner GxP Systems · CSV Lead
- Cares about
- The validation package, integrations and release management.
- Worries about
- A vendor release that breaks the validated state.
Information security and data protection
Can Veto
CISO · Data Protection Officer
- Cares about
- Hosting regions, subprocessors and supplier duties under NIS2.
- Worries about
- Case data with patient details held where the DPA does not allow it.
Procurement and finance
Can Veto
Category Manager R&D/IT Procurement · CFO
- Cares about
- Cost over the term, including migration and validation.
- Worries about
- Per-case or per-user fees that rise with each launch.
Regulatory consultant or CRO
Regulatory Consultant · Validation/CSV Consultant
- Cares about
- Keeping their role in submissions or safety work.
- Worries about
- Losing scope to the vendor’s own services team.
You sell the systems behind every filing and safety case.
What do regulatory and safety software vendors sell, and to whom?
Regulatory and safety software vendors sell RIM, submission, UDI and safety database systems to regulatory affairs and drug safety teams at biopharma and medtech companies. These systems track registrations, publish submissions, hold device data and process adverse event cases. Biotechs often buy their first safety database as a programme moves towards Phase 3 or a filing.
What vendors of this type sell
- Regulatory information management (RIM) and registration tracking
- Submission publishing and regulatory document management
- UDI and EUDAMED device data management
- Pharmacovigilance safety databases and case processing
- Signal detection and periodic safety reports
Which biopharma and medtech companies buy it
- Clinical-stage biotechs bringing safety data in-house from a CRO
- Mid-size and specialty pharma with marketed products
- Medtech and IVD makers registering devices in EUDAMED
- Top-tier biopharma consolidating regulatory and safety platforms
The milestone sets the date; QA sets the pace.
How does a RIM or safety database deal move at a biopharma company?
A RIM or safety database deal moves from a milestone or rule change through a business case, requirements, scripted demos and supplier qualification to contract and migration. By our estimate, mid-size pharma takes 4–18 months, and implementation then takes 6–12 months or more for an enterprise safety database. Durations show the buyer’s side, and stages overlap, so they add up to more than the cycle.
Stage by stage: what you do, what the biopharma or medtech company does, and what changes at the 4 stages where deals stall.
| Stage | What you do | What the biopharma or medtech company does | Today | With Panelhop |
|---|---|---|---|---|
| Targeting Typical time: 2–8 weeks | Segments by company type and waits for a request. | A Phase 3 start, a filing, an approval, an acquisition or a new rule creates the need. | Accounts are found when the Phase 3 news is out. Stalls: Missing the milestone window. By our estimate, buying starts 6–12 months before a Phase 3 start or a filing, so the safety database is chosen before the milestone shows up in registries. | Each week, accounts with a phase move, a filing date, an acquisition or a new safety leader arrive in your CRM, scored, with a brief naming the roles to reach. Signal Desk In-market accounts, weekly |
| Business case Typical time: 1–3 months | Offers ROI material and gap assessments. | The head of PV or RA writes a risk brief and seeks an executive sponsor and a budget line. | Nobody knows each account’s next milestone. | Each account carries its next phase, filing and safety-arrangement dates, and open deals are dated back from them. Leak Fix We build the fixes |
| Requirements Typical time: 3–8 weeks | Answers RFIs and shares pricing on request. | Writes a URS covering case volumes, products, countries and integrations. | RFIs go to vendors already on the approved supplier list. | Each account records whether you hold an MSA, a quality agreement or approved-supplier status, so your team can start supplier onboarding before the RFI lands. Leak Fix We build the fixes |
| Evaluation Typical time: 1–3 months, then 2–6 weeks of references | Runs scripted demos on the buyer’s own cases and submissions. | Scores fit, migration effort and validation support, then calls peers. | One function head carries the deal. Stalls: The platform module is ‘coming’. Accounts standardised on a broad platform wait for its own regulatory or safety module, because each new tool adds integration work and revalidation. | A role map per tier covers IT, validation, security and data protection, with missing roles enriched and coverage tracked per account. Leak Fix We build the fixes |
| Supplier qualification Typical time: 2–6 months | Hosts the supplier audit and answers security and data protection questions. | QA audits the vendor as a GxP supplier; security and the DPO review hosting and data transfers. | QA and the DPO first see you after the shortlist. Stalls: QA meets you after the shortlist. Supplier audit, security and data protection reviews start once a preferred vendor is chosen, so signature slips. | Supplier qualification becomes a stage with exit criteria, opened at discovery, and its days are tracked in the forecast. Your quality team owns the evidence. Leak Fix We build the fixes |
| Contract Typical time: 1–3 months, then 1–4 weeks for sign-off | Prices licences, migration and validation separately. | Legal, procurement and finance agree the MSA, DPA and quality agreement; the executive team signs. | Unfunded deals sit in the year-end forecast. Stalls: The deal misses the budget. A need found late in the year without a funded line waits for the next planning cycle, and biotech deals stall between financing rounds. | A deal risk score and forecast tracking flag deals without a funded budget line before the forecast call. Leak Fix We build the fixes |
| Migration Typical time: 6–12 months or more for an enterprise safety database | Migrates cases or registrations and delivers the validation package. | Validates, runs in parallel and goes live. | What sales promised about migration lives in one rep’s head. | A handoff document built from the deal records what was promised about case migration, validation and parallel running. Leak Fix We build the fixes |
| Expansion | Adds products, countries and modules. | Consolidates systems after acquisitions and reviews every module at renewal. | Customer acquisitions surface at renewal. | Panel Ops operates the renewal tasks and expansion triggers with your team, raises customer acquisitions in the weekly signal review and reports against the baseline every month. Panel Ops We run it monthly |
Put every account’s next milestone in the CRM.
How does Panelhop help RIM and pharmacovigilance vendors sell?
Panelhop helps regulatory and safety vendors by making each account’s next milestone visible, starting with a Panel Check (GTM audit) that baselines your pipeline by tier. Signal Desk (in-market accounts, weekly), Leak Fix (we build the fixes) and Panel Ops (we run it monthly) then work the stages that leak.
What we baseline and report
- Days from a phase move, filing or acquisition signal to your rep’s first touch, against the baseline
- Open deals with IT, QA and data protection engaged before the shortlist, against the baseline
- Days each deal spends in supplier qualification, against the baseline
Other vendor types in pharma and life sciences.
What other vendors sell to biopharma and medtech companies?
The same biopharma and medtech companies buy from these vendor types too, through different panels and pipelines.
- Vendor type
eClinical software
EDC, eCOA, eConsent, RTSM, CTMS and eTMF platforms sold to trial sponsors and CROs, priced per study, user or portfolio.
Read the pipeline - Vendor type
eQMS and quality management software
Cloud eQMS for document control, training, CAPA, audits and supplier quality, sold to device makers, biotechs, pharma sites and CDMOs.
Read the pipeline - Vendor type
Lab and manufacturing software
LIMS, ELN, MES and electronic batch record software sold to QC labs, manufacturing sites and CDMOs in pharma, biotech and medtech.
Read the pipeline - Vendor type
Commercial data and HCP intelligence
HCP, site, patient and access data and analytics for biopharma commercial, medical affairs, market access and patient services teams.
Read the pipeline
The words your buyers use, defined.
What do terms like “RIM” and “QPPV” mean?
Plain definitions of the terms that come up when you sell regulatory information and pharmacovigilance software to biopharma and medtech companies.
- RIM
- Regulatory information management: software that tracks a company’s product registrations, submissions, variations and commitments across countries, often linked to submission publishing.
- QPPV
- Qualified person responsible for pharmacovigilance: the named individual an EU marketing authorisation holder must have, accountable for its drug safety system.
- Safety database
- The validated system where a drug developer records, assesses and reports adverse event cases to regulators, and from which it runs signal detection and periodic safety reports.
- UDI
- Unique device identification: a code on each medical device and its packaging, with the device data held in databases such as FDA’s GUDID and the EU’s EUDAMED.
- EUDAMED
- The European database on medical devices. Its actor, UDI/device, notified body and market surveillance modules became mandatory on 28 May 2026.
- PSUR and DSUR
- Periodic safety reports: the PSUR for marketed products and the DSUR for products in clinical development, both submitted to regulators on a set schedule from the safety database.
Answers before your next biopharma or medtech company deal.
What do vendors of regulatory information and pharmacovigilance software ask about selling to biopharma and medtech companies?
When does a biotech buy its own safety database?
A biotech often buys its own validated safety database as a programme moves towards Phase 3, a filing or a launch. By then, case volumes are growing and the sponsor wants direct control of its safety data. The choice opens 6–12 months before the milestone, by our estimate, so pharmacovigilance vendors should track phase moves and filing dates for every account.
How long does it take to sell a pharmacovigilance or RIM system?
Selling a pharmacovigilance or RIM system to a mid-size pharma company takes 4–18 months by our estimate, typically about 9 months. Enterprise platforms at top-tier biopharma take an estimated 6–24 months. Supplier qualification can add an estimated 2–6 months, and implementation takes 6–12 months or more for an enterprise safety database, so biopharma buyers change these systems rarely and carefully.
How does EUDAMED affect regulatory software vendors?
EUDAMED creates demand for UDI and regulatory data tools at medtech and IVD makers. The first EUDAMED modules became mandatory on 28 May 2026, and devices already on the EU market that are still being placed on it must be registered in the UDI/device module by 28 November 2026. Device makers have to clean and submit device data at scale, so regulatory software vendors should know each target’s registration status.
Who buys pharmacovigilance software at a pharma company?
At a pharma company, the head of pharmacovigilance or global patient safety usually owns a safety database purchase, often with the QPPV. PV operations shape the requirements. IT and validation check integrations and the validation package, while security and the data protection officer review hosting and data transfers. Procurement and finance agree the terms, and the panel runs to 5–12 people, by our estimate.
Why do acquisitions matter for regulatory and safety software vendors?
Acquisitions matter because integration teams at biopharma companies decide which regulatory and safety systems to keep, and safety cases often migrate to one database. Purchases tend to follow 0–12 months after close, by our estimate. For a regulatory or safety software vendor, an acquired customer is a renewal risk and an acquiring prospect is an opening, so record every customer and prospect acquisition as an account event.
How do RIM and safety vendors get a meeting with the head of pharmacovigilance or regulatory affairs?
RIM and safety vendors get meetings with the head of pharmacovigilance or regulatory affairs at a biopharma or medtech company by writing about a dated milestone at that account. That milestone can be a Phase 3 start, a filing, an acquisition or a EUDAMED deadline. Regulatory leaders trust gap-assessment worksheets and regulator-led sessions, so open with a worksheet for that milestone. Regulatory and validation consultants can make the introduction.
Where the numbers come from.
Sources
Sourced figures link to their source below. Figures marked Illustrative, and figures given as estimates, are inferred from Panelhop research. Vendors appear only as types, never by name.
- European Commission, DG SANTE, EUDAMED: overview (2026)
- European Commission, DG SANTE, EUDAMED transition period: legacy and Regulation devices placed on the market before the mandatory use (2026)
- European Medicines Agency, Reform of the EU pharmaceutical legislation (2026)
- BPI (Bundesverband der Pharmazeutischen Industrie), citing Destatis structural statistics, Pharma-Daten 2025 (2026)
- Panelhop research, October 2026: our analysis of the vendors, buying panels, pipelines and triggers for regulatory information and pharmacovigilance software in pharma and life sciences, from public sources. Vendor names are not published.
Find where your pipeline to biopharma and medtech companies leaks.
